tbuckley/cabot-search huggingface dataset:
TRANSTHORACIC ECHOCARDIOGRAPHY VERSUS CARDIAC MAGNETIC RESONANCE FOR THE ASSESSMENT OF AORTIC REGURGITATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Anil Kumar Jonnalagadda, Christos A. Papanastasiou, Damianos Kokkinidis, Evangelos Oikonomou, Mario Garcia, Theodoros Karamitsos
Journal: Journal of the American College of Cardiology (2019)
Abstract 1281: Genomic structure variation in large screening for pediatric sarcoma therapy
Authors: Lijun Cheng, Pooja Chandra, Limei Wang, Karen Pollok, Pankita Pandya, Mary Murray, Jacquelyn Carter, Michael Ferguson, Mohammad Reza, Mashall Mark, Lang Li, Jamie Renbarger
Journal: Cancer Research (2018)

Abstract Complex chromosomal aberrations such as amplification and deletion of DNA copy number are frequently seen in sarcoma. Fifty-five DNA structure variation has been listed as standard clinical diagnosis for sarcoma by standard of National Comprehensive Cancer Network (NCCN). However, copy number variation (CNV) as a biomarker of drug treatment for pediatrics sarcoma is still unclear, especially for relapsed and high recurrent patients of pediatric sarcoma. The paper aims to detect the prognosis biomarkers for rhabdomyosarcoma, Ewing's sarcoma (ES), and osteosarcoma based on copy number variation for 128 FDA-approved cancer drugs systematically. The 182 copy number variation (CNV) profiles from clinical sarcoma patients across three types of sarcoma, including osteosarcoma, rhabdomyosarcoma and ES, are observed. Cox survival regression model is used to select significant cancer-related CNVs systematically by correlation with overall survival analysis. 532 significant common CNVs and 782 specific CNVs for different types of sarcoma are observed by p-value &amp;lt;0.01. By comparing with healthy persons, COSMIC database, 947 cancer cells and our INHOUSE tumor datasets, 32 out of 532 CNVs for specific sarcoma types are validated. This systematic CNV comparison makes it possible to map DNA copy number changes and identify chromosomal regions containing “target genes” responsible for tumor development and/or progression. Integrating large-scale drug screening with copy number variation analysis on 38 sarcoma cancer cells, 95 out of 532 are confirmed as drugs resistance and sensitive biomarkers for different types of sarcoma. 15 chemotherapies show strong signals connecting with 42 biomarkers, including genes MYC, RAD21, and RB1 amplification. By bridging molecular biomarkers between tumors and sarcoma cell lines, 5 optimum drugs associated with 14 enzyme biomarkers are recommended for pediatric rhabdomyosarcoma, ES, and osteosarcoma treatment respectively. The research not only detects copy number variations both of sarcoma cell lines and tumors, but also provides novel insights into drug biomarkers based on copy number amplification or deletion for bone sarcoma and soft tissue sarcoma, respectively. Citation Format: Lijun Cheng, Pooja Chandra, Limei Wang, Karen Pollok, Pankita Pandya, Mary Murray, Jacquelyn Carter, Michael Ferguson, Mohammad Reza, Mashall Mark, Lang Li, Jamie Renbarger. Genomic structure variation in large screening for pediatric sarcoma therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1281.
PROCEEDINGS OF THE FIFTY-SIXTH ANNUAL MEETING
Journal: American Journal of Psychiatry (1900)

Society was held jointly witli The Cooper Ornithological Society.The site of the joint meeting was the modern and comfortable campus of Montana State University in Bozeman, Montana.This second joint meeting of tlie 2 societies was conducted from 12 through 15 June 1975.The Executive Council of The ilson Ornithological Society held 2 meetings in a conference room at the Hedges North Residence Hall.Business meetings of The ilson Society were held in tlie meeting room in Johnson Hall.These proceedings detail tlie decisions made, awards presented, papers heard, friends well met, and presentations enjoyed in the beautiful Gallatin Valley of Montana.pleasant reception for early registrants was hosted Wednesday evening by the Sacajawea .\udubonSociety while the Executive Council of The Wilson Society and the Board of Directors of The Cooper Omitliological Society held their separate meetings.On Thursday morning the societies were welcomed in their General Session by Carl W. McIntosh.President of Montana State University.A full day of scientific papers followed.An evening film.Land of Shining Mountains, was presented by Louis M. Moos, photographer and lecturer.Well-organized birding trips were held to nearby localities for tlie early risers on Friday
Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): An epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)
Authors: M.Y. Williamson, A. Tomar, G.S. Jhuti, C. Revil, A. Kotzeva, K. Gururaj
Journal: Annals of Oncology (2019)
MG1124, a novel CEACAM1-targeted monoclonal antibody, has therapeutic potential as a combination partner of PD-1 inhibitors in NSCLC patients
Authors: E.H. Lee, J. Lee, M. Hur, H.-Y. Park, H.I. Yum, H. Nam, M.-Y. Oh, H. Choi, J. Kim, B.C. Cho, Y. Lim, J. Won
Journal: Annals of Oncology (2019)
Elusive Waste
Authors: Donald M. Berwick
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Long-Term Dabigatran Treatment Delays Alzheimer’s Disease Pathogenesis in the TgCRND8 Mouse Model
Authors: Marta Cortes-Canteli, Anna Kruyer, Irene Fernandez-Nueda, Ana Marcos-Diaz, Carlos Ceron, Allison T. Richards, Odella C. Jno-Charles, Ignacio Rodriguez, Sergio Callejas, Erin H. Norris, Javier Sanchez-Gonzalez, Jesus Ruiz-Cabello, Borja Ibanez, Sidney Strickland, Valentin Fuster
Journal: Journal of the American College of Cardiology (2019)

Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder with important vascular and hemostatic alterations that should be taken into account during diagnosis and treatment. This study evaluates whether anticoagulation with dabigatran, a clinically approved oral direct thrombin inhibitor with a low risk of intracerebral hemorrhage, ameliorates AD pathogenesis in a transgenic mouse model of AD. TgCRND8 AD mice and their wild-type littermates were treated for 1 year with dabigatran etexilate or placebo. Cognition was evaluated using the Barnes maze, and cerebral perfusion was examined by arterial spin labeling. At the molecular level, Western blot and histochemical analyses were performed to analyze fibrin content, amyloid burden, neuroinflammatory activity, and blood–brain barrier (BBB) integrity. Anticoagulation with dabigatran prevented memory decline, cerebral hypoperfusion, and toxic fibrin deposition in the AD mouse brain. In addition, long-term dabigatran treatment significantly reduced the extent of amyloid plaques, oligomers, phagocytic microglia, and infiltrated T cells by 23.7%, 51.8%, 31.3%, and 32.2%, respectively. Dabigatran anticoagulation also prevented AD-related astrogliosis and pericyte alterations, and maintained expression of the water channel aquaporin-4 at astrocytic perivascular endfeet of the BBB. Long-term anticoagulation with dabigatran inhibited thrombin and the formation of occlusive thrombi in AD; preserved cognition, cerebral perfusion, and BBB function; and ameliorated neuroinflammation and amyloid deposition in AD mice. Our results open a field for future investigation on whether the use of direct oral anticoagulants might be of therapeutic value in AD.
Clinical predictors for analgesic response to radiotherapy in patients with painful bone metastases
Authors: R. Habberstad, T.C. Frøseth, N. Aass, E. Bjerkeset, T. Abramova, E. Garcia-Alonso, M. Caputo, R. Rossi, J.W. Boland, C. Brunelli, J-Å Lund, S. Kaasa, P. Klepstad
Journal: Annals of Oncology (2019)
First national external quality assessment for the interpretation of somatic variants: Assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France
Authors: E. Rouleau, K. Leroy, K. Dufraing, A. Harlé, L. Lacroix, K. Vanwelden, M.G. Denis, A. Lamy, E. Dequeker
Journal: Annals of Oncology (2019)
Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Authors: A. Hepner, M.S. Carlino, D.B. Johnson, C.L. Gérard, S. Lo, L. Pallan, I.D. Silva, O.A. Michielin, G.V. Long, A.M. Menzies
Journal: Annals of Oncology (2019)
Clinical development of molecular-targeted therapies for non-small cell lung cancer through nationwide genome screening in Japan (LC-SCRUM-Japan)
Authors: S. Miyamoto, S. Matsumoto, K. Yoh, T. Kato, K. Nishino, S. Sugawara, M. Nakao, Y. Ohe, T. Seto, J. Sakakibara-Konishi, N. Furuya, K. Goto
Journal: Annals of Oncology (2019)
Clinical validation of a novel assay for the detection of diagnostic alterations in sarcomas
Authors: L. Mc Connell, O. Houghton, M. Catherwood, J. Gazdova, P. Stewart, A. Oniscu, P. Groenen, L. Kroeze, P. Taniere, A. Flanagan, A. Stobl, M. Salto-Tellez, D Gonzalez De Castro
Journal: Annals of Oncology (2019)
Ramucirumab in the treatment of refractory metastatic gastric cancer: Results from the RamSelGa trial
Authors: A. Tryakin, E. Perminova, D. Stroyakovsky, T. Titova, D. Yukalchuk, D. Ponomarenko, N. Beliak, G.M. Teletaeva, E. Ratner, A. Mochalova, O.O. Gordeeva, A. Meshcheryakov, A.S. Zhabina, S. Gamayunov, A. Smolin, A. Povyshev, M. Andrievsckih, M. Fedyanin, I. Tsimafeyeu, N. Besova
Journal: Annals of Oncology (2019)
When Prevention Works, Nothing Happens
Authors: Boris D. Lushniak
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Regorafenib in combination with paclitaxel for beyond first-line treatment of advanced esophagogastric cancer (REPEAT): A phase Ib trial with expansion cohort
Authors: M. Khurshed, C.I. Stroes, S. Schokker, S. van der Woude, R. Mathôt, M. Slingerland, J. de Vos-Geelen, M. van Oijen, O. van Delden, M. Weterman, C.J.A. Punt, M. Bijlsma, H.W.M. van Laarhoven
Journal: Annals of Oncology (2019)
Next-generation sequencing (NGS) in metastatic colorectal cancer (mCRC): Novel mutated genes and their effect on response to therapy (Alliance)
Authors: F. Innocenti, N. Rashid, M. Wancen, F.-S. Ou, X. Qu, S. Denning, M. Bertagnolli, C.D. Blanke, A. Venook, O. Kabbarah, H.J. Lenz
Journal: Annals of Oncology (2019)
Window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (SCCHN): Interim safety analysis
Authors: T. Richa, J.M. Johnson, D.M. Cognetti, A. Argiris, A. Luginbuhl, R. Zinner, R. Axelrod, V. Bar-Ad, R. Goldman, U. Rodeck, U. Martinez-Outschoorn, J.M. Curry
Journal: Annals of Oncology (2019)
Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Authors: H. Palmedo, S. Eschmann, A. Werner, I. Selinski, M.-O. Möllers, J. Kalinovsky, A. Benson, T. Poeppel
Journal: Annals of Oncology (2019)
Bronchial Reactivity: Hyporesponsiveness vs Hyperresponsiveness
Authors: W H Crosby
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
γδ T cells: A disappearing act with a big reveal
Authors: Julie M. Jameson
Journal: The Journal of Experimental Medicine (2018)

In this issue of JEM, Sandrock et al. (https://doi.org/10.1084/jem.20181439) compare the origin of IL-17–producing γδ T cells (Tγδ17) with other γδ T cell populations and demonstrate the role Tγδ17 cells play in skin pathology. Using two genetically modified mouse models, one with inducible γδ T cell–specific labeling and the other with conditional γδ T cell depletion, the authors find that Tγδ17 are mostly long-lived lymphocytes and that depleting γδ T cells protects mice from psoriasis.
GPs’ uptake of new prescribing guidance varies widely
Authors: Elisabeth Mahase
Journal: BMJ (2019)

General practices vary considerably in how quickly they adopt new prescribing guidance, an analysis of over 8000 practices has shown.1

Researchers from the University of Oxford set out to determine how clinicians varied in their response to new treatment guidance, using two examples and monitoring the change over five years.

They found that practices varied drastically in how quickly they started making changes and how swift the changes were. The authors said that these delays exposed the health system to “substantial …
TMOD-36. SUCCESSFUL GENERATION OF FIVE PATIENT-DERIVED ENDOGENOUS IDH1 MUTANT GLIOMA CELL LINES PROVIDES OPPORTUNITIES FOR DEVELOPMENT OF NEW TREATMENT STRATEGIES FOR IDH MUTANT GLIOMAS
Authors: Cassandra Verheul, Marielle Van Der Kaaij, Tessa Pierson, Trisha Kers, Ya Gao, Eduard Struys, Gajja Salomons, Clemens Dirven, Sieger Leenstra, Pim French, Martine Lamfers
Journal: Neuro-Oncology (2017)

Despite the high frequency of IDH mutations in low-grade gliomas and secondary glioblastomas, in vitro models with native IDH mutations remain scarce. Development of such models is essential to study the biology of IDH1 mutations and to develop new treatment strategies. Glioma samples were obtained directly from the operating theatre as solid resection material or CUSA aspiration, were dissociated and cells were cultured under serum-free conditions. IDH1 mutations were verified with Sanger sequencing. D2HG was measured by mass spectrometry. Cell viability was measured using an ATP-based viability assay. Drug screening was performed using an FDA-approved Oncology Drugs Set from NIH as well as with specific IDH1-mutant inhibitors. Attempts to establish a cell culture were undertaken on a total of eighty IDH1 mutant gliomas. From this series, five successful IDH1 mutant cell lines were obtained (i.e. those that remain in culture >10 passages while maintaining the IDH1-mutation). All five cell lines are 1p/19q intact, WHO grade III-IV and have an IDH1-R132H mutation. Production of the mutant IDH1 derived oncometabolite D2-HG was confirmed. Addition of IDH1-mutant inhibitor AGI-5198 resulted in differential and modest effects on 3 of the IDH1 mutant cell lines. One cell line lost its IDH1 mutation around passage 16, which indicates that at least some IDH1-mutant gliomas are no longer dependent on the mutation in vitro. In contrast, a different cell line gained a copy of IDH1-R132H without compromising its proliferation potential. Drug screening with a set of FDA-approved oncology drugs (n=107) revealed several candidates that strongly decrease cell viability at clinically-feasible concentrations. An orthotopic mouse model is in development to further assess the therapeutic potential of these agents. We have established a unique set of five native IDH-mutated cell lines, therewith providing opportunities to assess new therapeutic strategies for this subtype of malignant glioma.
Circuit aerobic and resistance exercise to target metabolic dysregulation in breast and prostate cancer survivors: The CARE trial study design.
Authors: Christina Marie Dieli-Conwright, Kyuwan Lee, Christina Chow, Kaylie Zapanta, Irene Kang, Jacek K. Pinski, Tanya B. Dorff
Journal: Journal of Clinical Oncology (2018)

TPS10126 Background: Breast and prostate cancer survivors are at an increased risk of developing comorbidities such as metabolic syndrome (MSY), diabetes, and cardiovascular disease exacerbated by cancer treatments. MSY is a cluster of risk factors including visceral adiposity, insulin resistance, hyperglycemia, hyperinsulinemia, low serum high-density lipoprotein cholesterol, and hypertension. Exercise is an effective strategy to target MSY and therefore, we designed a novel exercise intervention referred to as circuit aerobic and resistance exercise (CARE). Our primary objective is to determine whether a 16-week CARE intervention improves components of MSY among breast and prostate cancer survivors with the primary endpoint of MSY cumulative score. Methods: We are currently recruiting sedentary, overweight/obese (BMI > 25 kg/m2) women and men diagnosed with Stage I-III breast cancer or prostate cancer, respectively, from the USC Norris Comprehensive Cancer Center and Los Angeles County Hospital. Participants are randomized to either the CARE or Attention Control group. The CARE group participates in supervised exercise sessions 3 times per week for 16 weeks. CARE is a systematically progressed program of aerobic and resistance exercise performed in a circuit that begins at a low intensity and gradually increases to high intensity over the duration. The Attention Control group performs a home-based stretching program 3 days per week. At baseline (month 0), post-intervention (month 4), and follow-up (month 8), all participants are tested for MSY components. Statistical analyses for each outcome will involve mixed effects linear regression models. The sample size (25/arm within each cohort) reflects the need to obtain unbiased estimates of differences with reasonable precision. We will recruit an additional 90 patients (at present time n = 10) over the next 3 years. It is expected that this intervention will improve components of MSY in breast and prostate cancer survivors when compared to the Attention Control group, thus defining intervention and biomarker variables for more definitive trials. Clinical trial information: NCT03284346.
Local Venous Responses to Endotoxin in Humans
Authors: KiranBhagat, JoeCollier, PatrickVallance
Journal: Circulation (1996)

Background Septic shock is characterized by arterial and venous dilatation and decreased responsiveness to vasoconstrictors. We have developed a method to explore the effects and mechanisms of action of administration of endotoxin into a blood vessel in vivo. Methods and Results Endotoxin was instilled into a dorsal hand vein for 1 hour and then removed. A dose-response curve to norepinephrine was constructed before and 1, 2, 3, and 4 hours after endotoxin. In a separate study, dose-response curves to norepinephrine were constructed in two separate veins on the same hand, only one of which received endotoxin. Sympathetic-mediated venoconstrictor responses were also studied. Cyclooxygenase inhibitors, nitric oxide synthase inhibitors, and hydrocortisone were used to explore the mechanisms of the effects seen. Endotoxin caused a rightward shift in the dose-response curve to norepinephrine. The effect was greatest at 1 hour (maximal constriction: before endotoxin, 87±4%; after endotoxin, 52±8%; n=4; P<.05) a...
Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer
Authors: Lichun Ma, Maria O. Hernandez, Yongmei Zhao, Monika Mehta, Bao Tran, Michael Kelly, Zachary Rae, Jonathan M. Hernandez, Jeremy L. Davis, Sean P. Martin, David E. Kleiner, Stephen M. Hewitt, Kris Ylaya, Bradford J. Wood, Tim F. Greten, Xin Wei Wang
Journal: Cancer Cell (2019)

Cellular diversity in tumors is a key factor for therapeutic failures and lethal outcomes of solid malignancies. Here, we determined the single-cell transcriptomic landscape of liver cancer biospecimens from 19 patients. We found varying degrees of heterogeneity in malignant cells within and between tumors and diverse landscapes of tumor microenvironment (TME). Strikingly, tumors with higher transcriptomic diversity were associated with patient's worse overall survival. We found a link between hypoxia-dependent vascular endothelial growth factor expression in tumor diversity and TME polarization. Moreover, T cells from higher heterogeneous tumors showed lower cytolytic activities. Consistent results were found using bulk genomic and transcriptomic profiles of 765 liver tumors. Our results offer insight into the diverse ecosystem of liver cancer and its impact on patient prognosis.
Reversion of resistance to mTOR inhibitors with the addition of exemestane in patients with malignant PEComa
Authors: R. Sanfilippo, C. Fabbroni, E. Fumagalli, R. Bertulli, S. Stacchiotti, G. baldi, G. Fucà, C. Morosi, A. Gronchi, A.P.i. De Tos, P. Collini, P.G. Casali
Journal: Annals of Oncology (2019)
Utilization of real-world data to assess the effectiveness of immune checkpoint inhibitors (ICIs) in elderly patients with metastatic melanoma
Authors: D.S. Ernst, H. McConkey, L. Liu, M.O. Butler, T. Petrella, T. Baetz, R. Koneru, X. Song, T. Cheng, M.G. Smylie, S. Rajagopal, C. Mihalcioiu, F. Gwadry-Sridhar
Journal: Annals of Oncology (2019)